A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists